CD8A and neoplasm: Guo and colleagues conducted the first study to combine antiOX40 with antiPD-1 in an ovarian cancer model; the regimen expanded CD4+ and CD8+ T cells, reduced Treg and MDSC numbers, induced a local immunostimulatory milieu, and markedly inhibited tumor development (125).